

## Special Issue

# Health Technology Assessment (HTA) of New vaccines and New Target Groups and Impact Evaluation and Effectiveness of Current Vaccination Strategies

### Message from the Guest Editors

Dear colleagues,

In the current global health scenario, there is a strong need for evidence-based choices to rationalize the use of limited available resources and maximize results in terms of health, especially for prevention activities.

The aim of the Special issue is to collect HTA studies on vaccination that can provide careful and indepth analysis of both epidemiological/clinical data and organization vaccination practices, also including the economic evaluations of new vaccines (such as RSV and SARS-CoV-2) or new vaccination strategies. We hope research articles on the impact of vaccination programs analyzing the reduction of notifications, hospitalizations, or deaths due to vaccine-preventable diseases (measles, rubella, varicella, et al.) would be appreciated. Monitoring studies of vaccination coverage trends over time and seroepidemiological studies are also welcome.

The final objective is to give voice to all vaccination practices that, at an acceptable and sustainable cost, can improve the quality of life of all people.

---

### Guest Editors

Prof. Dr. Paolo Bonanni  
Dr. Angela Bechini  
Dr. Sara Boccalini

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/67999](https://mdpi.com/si/67999)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).